Drugs / DDH-LSD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07309471 | Mar 2026 → Jul 2028 expected | — | University Hospital, Basel, Switzerland | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DDH-LSD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07309471 ↗ |
| Known as | Didehydro-LSD | “Pharmacokinetics of Didehydro-LSD (DDH-LSD) Compared With LSD” NCT07309471 ↗ |
| Modality | Other / unclassified | “DDH-LSD is a newly synthesized lysergamide with LSD-like receptor activity but faster metabolism in vitro” NCT07309471 ↗ |
| Route | Oral | “Single oral dose of DDH-LSD at the dose determined in Substudy 1.” NCT07309471 ↗ |